mRNA Cancer Vaccines: Separating Hope from ‘Turbo Cancer’ Misinformation
A new study from the University of Florida suggests an experimental mRNA vaccine, when paired with existing immunotherapy drugs, significantly boosted anti-tumor effects in mice, offering a potential pathway toward a universal cancer vaccine. The findings, published today in Nature Biomedical Engineering, come as scientists worldwide are making rapid progress toward harnessing mRNA technology to fight cancer, with over 120 clinical trials underway testing its efficacy against various malignancies.
The research focused on stimulating the immune system broadly, rather than targeting specific tumor proteins. Researchers found that the vaccine revved up the immune response, prompting it to attack cancer cells as if fighting a virus. Specifically, the vaccine increased expression of the PD-L1 protein within tumors, making them more susceptible to immunotherapy. “This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus — so long as it is an mRNA vaccine — could lead to tumor-specific effects,” said Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the study’s senior author.
The potential of mRNA vaccines in cancer treatment builds on decades of research, but gained prominence following the successful development of mRNA vaccines for COVID-19. MRNA vaccines deliver instructions to the body’s cells to produce specific proteins, training the immune system to recognize and attack them. In cancer, this approach allows for the creation of highly targeted vaccines that can identify and eliminate tumor cells while sparing healthy tissue, according to the American Cancer Society.
Clinical trials are already exploring the use of personalized mRNA vaccines, such as those being tested for glioblastoma, an aggressive brain tumor. Early results indicate these vaccines can rapidly activate the immune system against the cancer and improve patient survival. A review published in PubMed in January 2025 noted the significant advancement mRNA vaccines represent in cancer treatment, with trials demonstrating potential across lung, breast, prostate, melanoma, pancreatic, and brain cancers.
However, the promise of mRNA cancer vaccines is shadowed by the spread of misinformation, particularly the false claim of “turbo cancer” – the unsubstantiated assertion that COVID-19 mRNA vaccines cause unusually aggressive cancers. This narrative gained traction on social media beginning in July 2023 and has continued into early 2026, relying on anecdotal evidence, misinterpretations of studies, and recycled myths about vaccines altering human DNA. Despite the lack of credible evidence, the claim has even been repeated by some public figures, including a UK cardiologist who falsely linked the vaccine to cancer diagnoses within the British royal family in September 2025, prompting immediate condemnation from the medical community.
Researchers who monitor online health conversations warn that such misinformation can have serious consequences. Inaccurate information about cancer treatment can influence patient decisions, leading them to forgo recommended therapies and potentially increasing their risk of death. Oncologists are increasingly finding themselves needing to address myths and misleading information patients encounter online.
The spread of misinformation about mRNA vaccines poses a threat to public confidence in a potentially life-saving technology. Experts emphasize the demand for proactive, transparent communication to counter false claims, build trust, and ensure that the public can make informed decisions about their health.